Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc.
2026 · Acquisition/Merger · $2.5B · Complete
Announcement Sentiment
90
Strongly positive
Outcome Score
75
Worked — the deal delivered on its rationale.
Servier acquired Day One Biopharmaceuticals for approximately $2.5 billion ($21.50 per share in cash, a ~68% premium), with the transaction completed on April 23, 2026 following expiration of the tender offer on April 22, 2026 and a subsequent second-step merger; Day One was delisted from Nasdaq and became a wholly owned subsidiary of Servier. The deal gives Servier Ojemda (tovorafenib), an oral brain-penetrant RAF kinase inhibitor approved in the US for pediatric low-grade glioma and under EU review, complementing Servier's existing glioma portfolio anchored by Voranigo (vorasidenib).